108 results on '"Morisco F"'
Search Results
2. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study
3. A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro
4. Clinical significance of time related fluctuations of AFP and PIVKA-II serum levels in single patients with cirrhosis undergoing surveillance for hepatocellular carcinoma
5. Does the gut play a pivotal role in the protective effect of coffee on liver damage?
6. Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy
7. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution
8. Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies
9. Long-term albumin administration improves survival in patients with decompensated cirrhosis: final results of the “ANSWER” study
10. Optimization of direct antiviral agent treatment schedule in hepatitis C virus genotype 3 infection: an Italian, multicentetric experience in real-life setting
11. Clinical characterization and economic impact evaluation of anti-HCV DAA treatment failure: real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER)
12. Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study
13. Quantification of Serum HBsAg is a Useful Parameter to Optimize Antiviral NUC Therapy Schedule in Chronic Hepatitis B
14. In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment
15. Adherence to Guidelines in Field-Practice: Progetto Epatocarcinoma Campania
16. Safety and Effectiveness of Sorafenib forthe Treatment of Hepatocellular Carcinoma in Patients with Diabetes
17. Efficacy and Safety of Percutaneous Laser Ablation Therapy for Treatment of Large Hepatocellular Carcinoma
18. Virological Failures to New Direct Acting Antivirals in a Real Life Setting May Require Unconventional Regimens for Re-Treatment
19. Early Evaluation of Alpha-Fetoprotein Response for Predicting Outcomes in Sorafenib Treated Patients May be Misleading
20. Coffee and Intestinal Permeability in a Mice Model of Non-Alcoholic Fatty Liver Disease
21. Metabolic Disorders across Hepatocellular Carcinoma in Italy
22. SAT-350 - A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro
23. SAT-007 - Does the gut play a pivotal role in the protective effect of coffee on liver damage?
24. FRI-166 - Clinical significance of time related fluctuations of AFP and PIVKA-II serum levels in single patients with cirrhosis undergoing surveillance for hepatocellular carcinoma
25. THU-297 - Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy
26. P0340 : Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): A multicenter case-control study
27. P0369 : Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients
28. P0915 : Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing
29. P0580 : Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: An extensive analysis of HBV genome
30. P0625 : A hyper-glycosylation of HBV surface major hydrophilic region characterizes HBV reactivation driven by immunosuppression and affects HBsAg recognition in vitro
31. P1047 ENTECAVIR EFFECTIVENESS IN NAIVE AND NUC EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B AND LIVER CIRRHOSIS: INTERIM ANALYSIS OF THE ITALIAN ENTAS COHORT STUDY
32. P729 HCV GENOTYPE 1A AND 1B: SIMILARITIES AND DIFFERENCES IN CLINICAL FEATURES, THERAPEUTIC OUTCOME AND PREDICTORS OF RESPONSE
33. SAT-073 - Safety and Effectiveness of Sorafenib forthe Treatment of Hepatocellular Carcinoma in Patients with Diabetes
34. SAT-342 - Coffee and Intestinal Permeability in a Mice Model of Non-Alcoholic Fatty Liver Disease
35. FRI-132 - Quantification of Serum HBsAg is a Useful Parameter to Optimize Antiviral NUC Therapy Schedule in Chronic Hepatitis B
36. THU-263 - In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment
37. THU-241 - Virological Failures to New Direct Acting Antivirals in a Real Life Setting May Require Unconventional Regimens for Re-Treatment
38. THU-094 - Efficacy and Safety of Percutaneous Laser Ablation Therapy for Treatment of Large Hepatocellular Carcinoma
39. THU-058 - Adherence to Guidelines in Field-Practice: Progetto Epatocarcinoma Campania
40. THU-078 - Metabolic Disorders across Hepatocellular Carcinoma in Italy
41. THU-059 - Early Evaluation of Alpha-Fetoprotein Response for Predicting Outcomes in Sorafenib Treated Patients May be Misleading
42. 209 ONLINE ANALYSIS OF BREATH BY PROTON TRANSFER REACTION TIME OF FLIGHT MASS SPECTROMETRY IN CIRRHOTIC PATIENTS
43. 763 ENTECAVIR EFFECT ON LIVER FUNCTION IN FIELD PRACTICE: INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B
44. 456 LONG-TERM CLINICAL, BIOCHEMICAL AND VIROLOGICAL OUTCOMES AFTER SUCCESSFUL HCV-THERAPY
45. 728 REACTIVATION OF HEPATITIS B OR C IN PATIENTS WITH IBD, RECEIVING IMMUNOSUPPRESSIVE DRUGS. A RETROSPECTIVE MULTICENTRE STUDY
46. 884 INTERFERON RELATED THYROID DISEASE IN 3414 NAIVE PATIENTS WITH CHRONIC HEPATITIS C
47. 954 RISK FACTORS OF AMINOTRANSFERASE ELEVATION IN A POPULATION OF VIRUS-FREE BLOOD DONORS. A MULTICENTRE STUDY
48. [269] THE SIZE OF LARGEST NODULE - NOT THE NUMBER OF NODULES - IS THE BEST PREDICTOR OF RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION
49. 267 Transarterial chemoembolisation vs embolisation for hepatocellular carcinoma. A comparative audit
50. 167 Outcome and complications of liver transplantation in older recipients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.